MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer

N. Bucay, K. Sekhon, T. Yang, S. Majid, V. Shahryari, C. Hsieh, Y. Mitsui, G. Deng, Z. L. Tabatabai, S. Yamamura, G. A. Calin, R. Dahiya, Y. Tanaka, S. Saini

Research output: Contribution to journalArticle

Abstract

A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region-miR-383-is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor-initiating capacity of CD44+ PCa cells. Also, 'anti-metastatic' effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.

Original languageEnglish (US)
Pages (from-to)2667-2679
Number of pages13
JournalOncogene
Volume36
Issue number19
DOIs
StatePublished - May 11 2017
Externally publishedYes

Fingerprint

MicroRNAs
Prostatic Neoplasms
Neoplasm Metastasis
Neoplasms
Stem Cells
Neoplastic Stem Cells
Loss of Heterozygosity
Theoretical Models
Down-Regulation
Chromosomes
Biomarkers

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Bucay, N., Sekhon, K., Yang, T., Majid, S., Shahryari, V., Hsieh, C., ... Saini, S. (2017). MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. Oncogene, 36(19), 2667-2679. https://doi.org/10.1038/onc.2016.419

MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. / Bucay, N.; Sekhon, K.; Yang, T.; Majid, S.; Shahryari, V.; Hsieh, C.; Mitsui, Y.; Deng, G.; Tabatabai, Z. L.; Yamamura, S.; Calin, G. A.; Dahiya, R.; Tanaka, Y.; Saini, S.

In: Oncogene, Vol. 36, No. 19, 11.05.2017, p. 2667-2679.

Research output: Contribution to journalArticle

Bucay, N, Sekhon, K, Yang, T, Majid, S, Shahryari, V, Hsieh, C, Mitsui, Y, Deng, G, Tabatabai, ZL, Yamamura, S, Calin, GA, Dahiya, R, Tanaka, Y & Saini, S 2017, 'MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer', Oncogene, vol. 36, no. 19, pp. 2667-2679. https://doi.org/10.1038/onc.2016.419
Bucay N, Sekhon K, Yang T, Majid S, Shahryari V, Hsieh C et al. MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. Oncogene. 2017 May 11;36(19):2667-2679. https://doi.org/10.1038/onc.2016.419
Bucay, N. ; Sekhon, K. ; Yang, T. ; Majid, S. ; Shahryari, V. ; Hsieh, C. ; Mitsui, Y. ; Deng, G. ; Tabatabai, Z. L. ; Yamamura, S. ; Calin, G. A. ; Dahiya, R. ; Tanaka, Y. ; Saini, S. / MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer. In: Oncogene. 2017 ; Vol. 36, No. 19. pp. 2667-2679.
@article{7221aa87fb4f4fa0918f45a8e93b7812,
title = "MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer",
abstract = "A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region-miR-383-is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor-initiating capacity of CD44+ PCa cells. Also, 'anti-metastatic' effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.",
author = "N. Bucay and K. Sekhon and T. Yang and S. Majid and V. Shahryari and C. Hsieh and Y. Mitsui and G. Deng and Tabatabai, {Z. L.} and S. Yamamura and Calin, {G. A.} and R. Dahiya and Y. Tanaka and S. Saini",
year = "2017",
month = "5",
day = "11",
doi = "10.1038/onc.2016.419",
language = "English (US)",
volume = "36",
pages = "2667--2679",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "19",

}

TY - JOUR

T1 - MicroRNA-383 located in frequently deleted chromosomal locus 8p22 regulates CD44 in prostate cancer

AU - Bucay, N.

AU - Sekhon, K.

AU - Yang, T.

AU - Majid, S.

AU - Shahryari, V.

AU - Hsieh, C.

AU - Mitsui, Y.

AU - Deng, G.

AU - Tabatabai, Z. L.

AU - Yamamura, S.

AU - Calin, G. A.

AU - Dahiya, R.

AU - Tanaka, Y.

AU - Saini, S.

PY - 2017/5/11

Y1 - 2017/5/11

N2 - A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region-miR-383-is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor-initiating capacity of CD44+ PCa cells. Also, 'anti-metastatic' effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.

AB - A major genomic alteration in prostate cancer (PCa) is frequent loss of chromosome (chr) 8p with a common region of loss of heterozygosity (LOH) at chr8p22 locus. Genomic studies implicate this locus in the initiation of clinically significant PCa and with progression to metastatic disease. However, the genes within this region have not been fully characterized to date. Here we demonstrate for the first time that a microRNA component of this region-miR-383-is frequently downregulated in prostate cancer, has a critical role in determining tumor-initiating potential and is involved in prostate cancer metastasis via direct regulation of CD44, a ubiquitous marker of PCa tumor-initiating cells (TICs)/stem cells. Expression analyses of miR-383 in PCa clinical tissues established that low miR-383 expression is associated with poor prognosis. Functional data suggest that miR-383 regulates PCa tumor-initiating/stem-like cells via CD44 regulation. Ectopic expression of miR-383 inhibited tumor-initiating capacity of CD44+ PCa cells. Also, 'anti-metastatic' effects of ectopic miR-383 expression were observed in a PCa experimental metastasis model. In view of our results, we propose that frequent loss of miR-383 at chr8p22 region leads to tumor initiation and prostate cancer metastasis. Thus, we have identified a novel finding that associates a long observed genomic alteration to PCa stemness and metastasis. Our data suggest that restoration of miR-383 expression may be an effective therapeutic modality against PCa. Importantly, we identified miR-383 as a novel PCa tissue diagnostic biomarker with a potential that outperforms that of serum PSA.

UR - http://www.scopus.com/inward/record.url?scp=84997719763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997719763&partnerID=8YFLogxK

U2 - 10.1038/onc.2016.419

DO - 10.1038/onc.2016.419

M3 - Article

C2 - 27893706

AN - SCOPUS:84997719763

VL - 36

SP - 2667

EP - 2679

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 19

ER -